Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy

References

• Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8–29
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy.[see comment]. J Clin Oncol 2002; 20: 3376–85
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Million RR, Bova FJ. Analysis of time-dose factors in clinically positive neck nodes treated with irradiation alone in squamous cell carcinoma of the head and neck. Int J Radiat Oncol, Biol, Phys 1984; 10: 639–43
   PubMed Web of Science ®Google Scholar
• Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. [see comment] [erratum appears in JAMA 1997 Jul 9;278:118]. JAMA 1997; 277: 1445–51
   PubMed Web of Science ®Google Scholar
• Roach M 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. [see comment]. Int J Radiat Oncol, Biol, Phys 1994; 28(1)33–7
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Tomee W, Patel R, Chappell R, Ritter M. 3D-ultrasound guided radiation therapy in the post-prostatectomy setting. Tech Cancer Res Treat 2003; 2: 455–8
   Google Scholar
• Tome W, Orton N. On the use of optically guided 3D-ultrasound for daily in room target localization. Med Phys 2005; 32: 2066–7
   Google Scholar
• Patel RR, Orton N, Tome WA, Chappell R, Ritter MA. Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer. Radiother Oncol 2003; 67: 285–94
   Google Scholar
• Shanahan TG, Mehta MP, Bertelrud KL, Buchler DA, Frank LE, Gehring MA, et al. Minimization of small bowel volume within treatment fields utilizing customized “belly boards”. Int J Radiat Oncol, Biol, Phys 1990; 19: 469–76
   PubMed Web of Science ®Google Scholar
• Langen KM, Zhang Y, Andrews RD, Hurley ME, Meeks SL, Poole DO, et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol, Biol, Phys 2005; 62: 1517–24
   PubMed Web of Science ®Google Scholar
• Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 2003; 69: 201–7
   PubMed Web of Science ®Google Scholar
• Löf J. Development of a general framework for optimization of radiotherapy. PhD thesis. Stockholm: Department of Medical Radiation Physics, Stockholm University; 2000.
   Google Scholar
• Löf J, Lind B, Brahme A. Optimal radiation beam profiles considering the stochastic process of patient positioning in fractionated radiation therapy. Inverse Problems 1995; 11: 1189–209
   Google Scholar
• Orton NP, Tome WA. The impact of daily shifts on prostate IMRT dose distributions. Med Phys 2004; 31: 2845–48
   Google Scholar
• Fowler JF. Brief summary of radiological principles in fractionated radiation therapy. Semin Radiat Oncol 1992; 2: 16–21
   Google Scholar
• Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol, Biol, Phys 2001; 50: 1021–31
   PubMed Web of Science ®Google Scholar
• Wang JZ, Li XA, Yu CX, DiBiase SJ. The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol, Biol, Phys 2003; 57: 1101–8
   PubMed Web of Science ®Google Scholar
• Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol, Biol, Phys 1997; 37: 3–11
   PubMed Web of Science ®Google Scholar
• Tome WA, Fowler JF. On cold spots in tumor subvolumes. Med Phys 2002; 29: 1590–8
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. [see comment]. Int J Radiat Oncol, Biol, Phys 2001; 51: 988–93
   PubMed Web of Science ®Google Scholar
• Song S, Tome WA, Mehta MP, Harari PM. Emphasizing conformal avoidance versus target definition for IMRT planning in H&N cancer. Int J Radiat Oncol, Biol, Phys 2003; 57S: s299–2300
   Google Scholar
• Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681–6
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Von Knobloch R, Varga Z, Hofmann R, Engelmann V. Extended pelvic lymphadenectomy in men undergoing radical prostatectomy – unupdate of >300 cases. J Clin Oncol 2004;22:4095 (abst 4612).
   Google Scholar
• Seaward SA, Weinberg V, Lewis P, Leigh B, Phillips TL, Roach M 3rd. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J Sci Am 1998; 4: 370–7
   PubMed Web of Science ®Google Scholar
• Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. NCI Monographs 1988; 7: 47–60
   Google Scholar
• McGowan DG. The value of extended field radiation therapy in carcinoma of the prostate. Int J Radiat Oncol, Biol, Phys 1981; 7: 1333–9
   PubMed Web of Science ®Google Scholar
• Perez CA, Michalski J, Brown KC, Lockett MA. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. IntJournal of Radiat Oncol, Biol, Phys 1996; 36: 573–84
   Google Scholar
• Ploysongsang S, Aron BS, Shehata WM, Jazy FK, Scott RM, Ho PY, et al. Comparison of whole pelvis versus small-field radiation therapy for carcinoma of prostate. Urology 1986; 27: 10–6
   Google Scholar
• Rangala N, Cox JD, Byhardt RW, Wilson JF, Greenberg M, Lopes da Conceicao A. Local control and survival after external irradiation for adenocarcinoma of the prostate. Int J Radiat Oncol, Biol, Phys 1982; 8: 1909–14
   PubMed Web of Science ®Google Scholar
• Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. [see comment]. J Clin Oncol 2003; 21: 1904–11
   PubMed Web of Science ®Google Scholar
• Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77–06. Int J Radiat Oncol, Biol, Phys 1988; 15: 1307–16
   PubMed Web of Science ®Google Scholar
• Aristizabal SA, Steinbronn D, Heusinkveld RS. External beam radiotherapy in cancer of the prostate. The University of Arizona experience. Radiother Oncol 1984; 1: 309–15
   PubMedGoogle Scholar
• Perez AA, Pilepich MV, Zivnuska F. Tumor control in definitive irradiation of localized carcinoma of the prostate. Int J Radiat Oncol, Biol, Phys 1986; 12: 523–31
   PubMed Web of Science ®Google Scholar
• Rosen E, Cassady JR, Connolly J, Chaffey JT. Radiotherapy for prostate carcinoma: The JCRT experience (1968–1978). II. Factors related to tumor control and complications. Int J Radiat Oncol, Biol, Phys 1985; 11: 723–30
   Google Scholar
• Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate. Int J Radiat Oncol, Biol, Phys 1988; 14: 701–9
   PubMed Web of Science ®Google Scholar
• Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? [see comment]. J Urol 2003; 169: 849–54
   PubMed Web of Science ®Google Scholar
• Das IJ, Lanciano RM, Movsas B, Kagawa K, Barnes SJ. Efficacy of a belly board device with CT-simulation in reducing small bowel volume within pelvic irradiation fields. Int J Radiat Oncol, Biol, Phys 1997; 39: 67–76
   PubMed Web of Science ®Google Scholar
• Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Padhani AR, Webb S, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol, Biol, Phys 2000; 48: 649–56
   PubMed Web of Science ®Google Scholar
• Sanguineti G, John B, Franzone P, Culp L, Sosa M, Cavey M, et al. IMRT to treat the pelvic nodes while escalating the dose to the prostate gland: Acute toxicity data in 45 consecutive patients. Int J Radiat Oncol, Biol, Phys 2005; 60(1S)s446(abstract 2217)
   Google Scholar
• Li XA, Wang JZ, Jursinic PA, Lawton CA, Wang D. Dosimetric advantages of IMRT sumultanueous integrated boost for high-risk prostate cancer. Int J Radiat Oncol, Biol, Phys 2005;61(4).
   Google Scholar
• Price RA, Hannoun-Levi J, Ma CC, Pollack A. Pelvic lymphatic coverage in the treatment of prostate cancer with intensity modulated radiation therapy: A feasibility study. Int J Radiat Oncol, Biol, Phys 2004; 60(S1)s635(abstract 2491)
   Google Scholar
• Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol, Biol, Phys 2002; 53: 904–12
   PubMed Web of Science ®Google Scholar
• Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol, Biol, Phys 2003; 56: 1093–104
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: What is it, really? [comment]. Radiother Oncol 2005; 76: 1–3
   PubMed Web of Science ®Google Scholar
• Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial.[see comment]. Int J Radiat Oncol, Biol, Phys 2002; 53: 1097–105
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol, Biol, Phys 2002; 53: 1111–6
   PubMed Web of Science ®Google Scholar
• Keller H, Tome W, Ritter MA, Mackie TR. Design of adaptive treatment margins for non-negligible measurement uncertainty: Application to ultrasound-guided prostate radiation therapy. Phys Med Biol 2004; 49: 69–86
   Google Scholar